All In Biotech

Drug Trial Radar · NCT06159725

A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

A Phase 1b/2a Study To Evaluate The Safety Of CMTX-101 In Combination With Inhaled Antibiotics In People With Cystic Fibrosis Chronically Infected With Pseudomonas Aeruginosa

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

43

Actual

Start

Jun 24, 2024

Primary completion

Nov 14, 2025

Study completion Nov 14, 2025

Sponsor

Lead sponsor
Clarametyx Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Dec 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics. The goal of this clinical trial is to assess the safety and tolerability of CMTX-101 in people with cystic fibrosis (pwCF). The main questions the study aims to answer are: * Are single doses of CMTX-101 IV infusion safe and tolerated * What is the pharmacokinetic (PK) profile of single doses of CMTX-101 * Do single doses of CMTX-101 induce development of anti-drug antibodies (ADA) and neutralizing antibodies (Nabs)

Conditions

  • Persistent Infection
  • Cystic Fibrosis

Interventions

  • CMTX-101Drug

    CMTX-101 is a humanized monoclonal antibody administered as a single IV infusion over approximately 60 minutes.

  • PlaceboDrug

    Placebo is normal saline administered as a single IV infusion over approximately 60 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and % of participants experiencing adverse events following a single IV infusion of CMTX-101Time frame: Day 1 to Day 28
  2. Number and % of participants experiencing serious adverse events following a single IV infusion of CMTX-101Time frame: Day 1 to Day 28

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama, Birmingham

    Birmingham, Alabama

  • Stanford University

    Palo Alto, California

  • University of California, San Francisco

    San Franciso, California

  • National Jewish Health

    Denver, Colorado

  • Central Florida Pulmonary Group, PA

    Orlando, Florida

  • St Luke's Sleep Medicine and Research Center

    Boise, Idaho

  • Cystic Fibrosis Institute

    Northfield, Illinois

  • University of Kansas

    Kansas City, Kansas

  • Johns Hopkins University

    Baltimore, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • New York Medical College

    Hawthorne, New York

  • Lenox Hill Hospital

    New York, New York

  • Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Nationwide Children's Hospital

    Columbus, Ohio

  • PennState Health

    Hershey, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Vanderbilt University

    Nashville, Tennessee

  • University of Utah

    Salt Lake City, Utah

  • Virginia Commonwealth University

    Richmond, Virginia

  • Seattle Children's Hospital

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.